BridgeBio posts early data for gene therapy targeting Canavan disease

Jun. 22, 2022 11:12 AM ETBridgeBio Pharma, Inc. (BBIO)By: Dulan Lokuwithana, SA News Editor

Diagnostic form with diagnosis Canavan disease and pills.

designer491/iStock via Getty Images

The shares of BridgeBio Pharma (NASDAQ:BBIO) traded higher in the morning hours Wednesday after the clinical-stage biotech announced encouraging data from the first two subjects who received the company’s Canavan disease candidate BP-812 in a Phase 1/2 clinical trial.

An ultra-rare and fatal disorder, Canavan disease is caused by a mutation of the ASPA gene that codes for aspartoacylase (ASPA), a protein that breaks down a compound called N-acetylaspartate (NAA). Genetically inherited Canavan disease has no approved therapies.

Highlights of the results include a 77% decline of NAA in the cerebrospinal fluid of the first patient six months after the treatment.

Meanwhile, the second patient was found to have an 89% reduction of NAA in CSF at month three post-treatment.

A decline in brain NAA signals that the AAV9-based gene therapy candidate BP-812 reached its target behind the blood-brain-barrier expressing the functional ASPA enzyme, BridgeBio (BBIO) said.

So far, none of the patients have experienced a drug-related serious adverse event, and BBP-812 was well tolerated, the company added.

BridgeBio (BBIO) anticipates more data from the trial later this year.

Read: Seeking Alpha contributor Avisol Capital Partners thinks that BridgeBio (BBIO) has yet to de-risk its business model.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.